CVKD vs PSA · $20.2M cap vs rev $1.23B
Cadrenal Therapeutics, Inc. Common Stock (CVKD) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a biotechnology company listed on US.
PSA (PSA) common stock.
CVKD does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
CVKD currently screens at market cap $20.2M. PSA currently screens at market cap $0.
Not investment advice. Open the CVKD and PSA stock pages for the full models.
Not investment advice.